MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income
$31,111K
Accrued expenses and
other
$13,154K
Depreciation and
amortization
$10,938K
Stock-based compensation
$6,944K
Deferred income taxes
$3,245K
Inventory, net
-$3,209K
Loss on disposal of
property and equipment
-$4K
Net cash provided by
operating activities
$41,802K
Canceled cashflow
$26,803K
Net (decrease)
increase in cash, cash...
-$39,584K
Canceled cashflow
$41,802K
Net proceeds from
shares issued under...
$130K
Maturity of
available-for-sale securities
$72,024K
Accounts receivable, net
$21,281K
Post-marketing commitment
liability
-$2,412K
Operating lease assets and
liabilities, net
$1,805K
Accounts payable
-$453K
Provision for credit loss
recovery
-$362K
Prepaid expenses and
other
$325K
Other current assets
$165K
Net cash used in
financing activities
-$45,198K
Canceled cashflow
$130K
Net cash used in
investing activities
-$36,188K
Canceled cashflow
$72,024K
Payment of debt
$44,440K
Payment of exit costs
$888K
Purchase of
available-for-sale securities
$108,141K
Purchase of property and
equipment
$71K
Back
Back
Cash Flow
source: myfinsight.com
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)